Biolight Brand Guidelines: The 1993 Zhuhai Monitor Maker That Moved Into Kidney Care

A joint venture on the Pearl River Delta.

Biolight began in Zhuhai, the coastal city in Guangdong province that faces Macau, in 1993. The company’s own history gives its first form as Zhuhai Baolaite Electronics Co., Ltd., a joint venture; 宝莱特, read Baolaite, remains its Chinese name, while English-language material uses Biolight. The company does not name its founders in its published history.

Its timeline then moves through the steps of a Chinese manufacturer growing up. In 2001, the company says, it was approved by what was then the Ministry of Foreign Trade and Economic Cooperation to convert as a whole into a joint-stock company. In 2003, it says, the National Development and Reform Commission named it a national industrialisation base for multi-parameter monitors, the bedside screens that show several vital signs at once. In 2008 it was recognised, by its account, among the first group of companies certified as high-tech enterprises under China’s national scheme.

The decisive date was 19 July 2011, when Guangdong Biolight Meditech listed on ChiNext, the growth board of the Shenzhen Stock Exchange. Chinese Wikipedia’s list of ChiNext companies gives that date and records the company as based in Zhuhai, matching the company’s own account. Biolight has remained a listed company since then, and its legal name today is Guangdong Biolight Meditech Co., Ltd.

By its own count it has now been at work for “over three decades,” and its English website closes on the line “Empower global healthcare, Guard the light of hope and life.” In Chinese the company uses a shorter four-plus-four-character motto, 厚德精工 守护健康, which pairs integrity and careful workmanship with looking after health.

Monitors and oximeters, then dialysis.

Biolight’s first products for export were monitoring devices, and the clearest dated record of them sits in the United States Food and Drug Administration’s 510(k) database, where makers file to market devices in the US. The first clearance under the Guangdong Biolight Meditech name, dated 12 September 2008, covers the M70 fingertip pulse oximeter and the M700 handheld oximeter. Clearances followed for an M series of patient monitors in 2010, the AnyView monitors in 2012, the TruScope series in 2013, and A series and Q series monitors in 2014.

The same database shows the range widening around the bedside. Biolight filed fetal monitors, a handheld monitor and a digital electrocardiograph in 2014. In 2016 came an electronic thermometer, a vital-signs monitor and a central monitoring system, followed by the TruScope Ultra patient monitor in 2017 and another patient monitor in 2019. The earlier filings carry a Shanghai address, and from 2016 they give Zhuhai.

The company now describes its business in three parts. Its Chinese website lists life information and support, its term for monitoring; kidney care; and home or general health products. The English site lists the same ground more plainly: patient monitors, dialysis products and home care.

Kidney care is the newer arm. The company says that in 2012 it set out to build a complete industry chain for kidney-disease care in China, from equipment to consumables, and that by 2017 it was the first Chinese company to have a combined haemodialysis production, sales and research base in Germany; that ranking is its own claim. It also says construction of a blood-purification industrial base and research centre began in 2020 and that the site opened in 2024.

The company lists honours of its own: a China listed-companies award for innovation in its industrial chain in 2017, a first prize in the Guangdong provincial science and technology awards in 2018, an innovation research institute set up in 2021, and recognition in 2022 as a provincial benchmark project for industrial internet use. In 2026 its news pages invited visitors to its stand at Hospitalar, the medical trade fair in São Paulo.

Design and documentation.

Respiratory care and patient monitoring sit in two places at once: the hospital ward and the patient’s home. Companies in this field make ventilators, CPAP and bi-level machines, oxygen concentrators, pulse oximeters and bedside monitors, and the way they present themselves usually follows the device to wherever it is used — a ventilator beside an intensive care bed, a small machine on a bedside table at home, a clip on a fingertip.

Their pictures tend to fall into a few familiar scenes. In hospital settings, clinicians stand at monitors with waveform screens showing pressure, flow or oxygen saturation; at home, patients sleep with a mask on or carry a portable concentrator through an ordinary day. Patient stories, often tied to a named model, sit alongside product pages written for respiratory therapists, doctors and home-care providers.

The field also meets in public at medical congresses and trade fairs. The European Respiratory Society congress, the American Thoracic Society conference and the Medica fair in Düsseldorf are among the gatherings where respiratory and monitoring products are shown to clinicians and buyers, and company news is often timed around them.

The companies in this guide differ widely in age, size and ownership — family firms, units of larger groups and makers that have changed hands several times. Each section sets out what can be checked about one brand: who founded it, who owns it now, what it makes and what it says about itself, with the company’s own claims marked as its own. Where sources disagree on a date or an owner, both versions are given.

One name in two scripts.

Biolight presents itself in two languages that do not quite mirror each other. Its Chinese site is built around the name 宝莱特 and a moral motto about integrity and workmanship; its English site, run under a separate global address, uses the Biolight name with a looser line about light, hope and life.

The English name is not unique. The FDA database also lists an unrelated Swedish company, Biolight AB of Stockholm, and a Biolight International AB with a Minneapolis address, both filing devices of their own; the website at biolight.com belongs to a separate spectroscopy software business. The Chinese manufacturer’s documents use the full form, Guangdong Biolight Meditech, and its domains are built on the letters BLT.

Its colours and lettering are not described in any published guideline, so nothing here should be read as an official brand standard. What the record does show is a company whose identity has moved with its products: from a monitor maker filing oximeters and bedside screens with the FDA in 2008, to a listed group that now gives dialysis equal billing with monitoring.

For a design guide, Biolight shows how a Chinese device maker can carry one name in two scripts and two registers while its product lines change underneath. Compare Comen, another Guangdong monitor maker, and Philips, another maker of patient monitors. For this guide we use a teal, a deep green-black and an amber with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Biolight’s identity on hand — save it to a board in the Made Good inspiration library.